Welcome to LookChem.com Sign In|Join Free

CAS

  • or

76322-06-0

Post Buying Request

76322-06-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

76322-06-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 76322-06-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,6,3,2 and 2 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 76322-06:
(7*7)+(6*6)+(5*3)+(4*2)+(3*2)+(2*0)+(1*6)=120
120 % 10 = 0
So 76322-06-0 is a valid CAS Registry Number.

76322-06-0Relevant articles and documents

An improved and scale-up synthesis of 6-hydroxybenzofuran

Song, Shu-Yong,Lu, He-Lin,Wang, Gui-Fei,Yang, Yi-Qiu,Huang, Yun-Sheng

, p. 4433 - 4442 (2016)

An optimized process for the preparation of 6-hydroxybenzofuran is described. This process consists of three steps: the reaction of 2-hydroxy-4-methoxybenzaldehyde with chloroacetic acid, the formation of the 6-methoxybenzofuran in acetic anhydride, and t

Rhodium-Catalyzed Intermolecular Cyclopropanation of Benzofurans, Indoles, and Alkenes via Cyclopropene Ring Opening

Jeyaseelan, Rubaishan,Lautens, Mark,Ross, Rachel J.

supporting information, (2020/06/29)

The generation of metal carbenoids via ring opening of cyclopropenes by transition metals offers a simple entry into highly reactive intermediates. Herein, we describe a diastereoselective intermolecular rhodium-catalyzed cyclopropanation of heterocycles and alkenes using cyclopropenes as carbene precursors with a low loading of a commercially available rhodium catalyst. The reported method is scalable and could be performed with catalyst loadings as low as 0.2 mol %, with no impact to the reaction yield or selectivity.

S1P RECEPTORS MODULATORS

-

Page/Page column 66; 67, (2010/04/30)

The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 76322-06-0